Organ‐on‐chip platforms combined with high‐throughput sensing technology allow bridging gaps in information presented by 2D cultures modeled on static microphysiological systems. While these platforms do not aim to replicate whole organ systems with all physiological nuances, they try to mimic relevant structural, physiological, and functional features of organoids and tissues to best model disease and/or healthy states. The advent of this platform has not only challenged animal testing but has also presented the opportunity to acquire real‐time, high‐throughput data about the pathophysiology of disease progression by employing biosensors. Biosensors allow monitoring of the release of relevant biomarkers and metabolites as a result of physicochemical stress. It, therefore, helps conduct quick lead validation to achieve personalized medicine objectives. The organ‐on‐chip industry is currently embarking on an exponential growth trajectory. Multiple pharmaceutical and biotechnology companies are adopting this technology to enable quick patient‐specific data acquisition at substantially low costs. Organ‐on‐chip platforms combined with high‐throughput sensing technology allow bridging gaps in information presented by 2D cultures modeled on static microphysiological systems. Miniaturized biosensors systems and advanced tissue fabrication procedures enable researchers to create multiple tissues on a chip with a high degree of control over experimental variables for high‐content screening applications.